Longitudinal Audiological and Vestibular Follow-up in Adult Cancer Patients Receiving Platinum-Based Chemotherapy

Platinum-based chemotherapy is widely used in cancer care but carries a substantial risk of cochleotoxicity and vestibulotoxicity. This study aimed to characterize early (3-month) and long-term (1-year) auditory and vestibular effects of platinum derivatives in adults, with the goal of improving monitoring strategies.

Audiologists working with oncology teams should consider structured longitudinal monitoring of both hearing and vestibular function in patients on platinum-based chemotherapy, as early detection of toxicity may allow treatment modification; this study reinforces — and may refine — existing ototoxicity monitoring guidelines.

Platinum-based chemotherapy is widely used and its ototoxic and vestibulotoxic side effects are a significant survivorship concern; longitudinal data characterizing the timeline of these toxicities can directly improve monitoring protocols and quality of life for cancer survivors.

1. 01Longitudinal study tracks both hearing loss (cochleotoxicity) and balance dysfunction (vestibulotoxicity) in adult cancer patients on platinum chemotherapy.
2. 02Published in JARO (Journal of the Association for Research in Otolaryngology), a leading audiology/otology research journal.
3. 03Early audiological and vestibular changes were characterized over serial follow-up assessments.
4. 04Findings are relevant to developing or updating ototoxicity monitoring protocols in oncology settings.
5. 05Both cochlear and vestibular toxicity pathways were assessed, providing a more complete picture of platinum drug side effects.

PMID

42443713

DOI

10.1007/s10162-026-01062-y.

Journal

Journal of the Association for Research in Otolaryngology

Publication type

research_article

Evidence level

2b

Population

Adult cancer patients receiving platinum-based chemotherapy

Intervention

Platinum-based chemotherapy with longitudinal audiological and vestibular monitoring